Family Office Of America, Inc.
Family Office of America, Inc. is a U.S.-based medical device company that appears to be in an early commercial stage, with filings showing capital raising and equity-based compensation activity rather than established operating revenue. The company’s disclosed history includes a subsidiary relationship with mPathix Health, Inc. and a license agreement tied to Life Care Medical Devices Limited, suggesting a product-development and commercialization model in surgical and medical instruments.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaCore medical device products and apparatus intended for clinical or procedural use.
Technology rights and know-how obtained through licensing arrangements for medical products.
Internal development, regulatory preparation, and commercialization support around device launch.
Asiakkaat
The company’s likely customers are healthcare providers, distributors, and other commercial partners that buy or license medical device products and related technology. Because the filings emphasize financing, warrants, and a license agreement, the business appears oriented toward building a product platform before broad market penetration. Demand would depend on clinical adoption, regulatory clearance, and the ability to convert development assets into sellable medical products.
Hospitals, clinics, and procedural centers that would purchase or use medical devices in care delivery.
Channel partners that could buy devices in bulk and resell into healthcare markets.
Partners that may license technology or support product commercialization and market access.
Investors providing capital through private placements to fund operations and development.
Strategia
The company’s near-term strategy appears focused on financing the business, advancing medical device-related assets, and building a path to commercialization. The disclosed private placement and consulting warrants suggest management is prioritizing capital formation and execution capacity before scale revenue. The license agreement with Life Care Medical Devices Limited indicates a strategy of using external technology rights rather than relying solely on in-house invention.
The company is still funding development and corporate activity through private placements.
Licensed technology can shorten time to market versus building products from scratch.
Sustainable value depends on converting development-stage assets into marketable products.
Maantiede
The company is headquartered in the United States, and the available filings do not disclose meaningful country-level revenue or operating geography. Based on the disclosed license agreement and SEC reporting, the business is primarily U.S.-centric at this stage, with any future expansion likely tied to medical device commercialization and distribution. Geographic exposure is therefore more about regulatory jurisdiction and market access than current revenue diversification.
Riskit
The company faces classic development-stage medical device risks: limited operating history, dependence on external financing, and uncertainty around product commercialization. Because the business relies on licensed technology and equity issuance, execution risk, dilution risk, and valuation risk are likely more important than near-term operating margin pressure. Regulatory, clinical adoption, and intellectual property risks are also material in surgical and medical instruments.
The company raised capital through a private placement and issued warrants, indicating reliance on external funding.
Kohdistuu: Common share issuance and warrant overhang
Medical device businesses must convert development assets into clinically adopted products, which is uncertain.
Kohdistuu: Licensed device technology and product launch execution
Surgical and medical instruments are subject to healthcare regulation, quality systems, and market clearance requirements.
The company references a license agreement, so access to technology may depend on contractual terms and counterparties.
Kohdistuu: mPathix Health / Life Care Medical Devices Limited arrangement
Kirjanpito
Harkinnanvaraiset erätThe company granted warrants to executives/consultants and states they will be revalued each reporting period.
Vaikutus: Can create non-cash expense and earnings volatility
Common shares were sold in a Regulation D offering, affecting capital structure and dilution.
Vaikutus: Changes shareholders' equity and per-share metrics
Warrants were issued for consulting services and valued at grant date.
Vaikutus: Affects operating expenses and APIC
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Orchestra BioMed Holdings, Inc.
OBIO · Surgical & Medical Instruments & Apparatus
OrthoPediatrics Corp
KIDS · Surgical & Medical Instruments & Apparatus
Pacific Health Care Organization Inc
PFHO · Services-Misc Health & Allied Services, NEC
Healthcare AI Acquisition Corp.
Blank Checks
Femasys Inc
FEMY · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026